News | November 07, 2022
Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Revenue is up 23% whereas Profit After Tax expands 29% for the company
According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Esiloc was launched at the biggest doctor engagement webinar involving more than 12,000 doctors across the country
None of the observations are related to data integrity and Alembic Pharmaceuticals management believes that they are addressable
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
Both the partners will work towards bringing Aster Pharmacy’s in-house quality care products to serve the healthcare needs of the local population in KSA
Subscribe To Our Newsletter & Stay Updated
